RE:RE:revenueYeah, even with 0 growth from here on in, you're looking at 22-25M in revenue for 2015. Using the 50% growth guidance Mr. Harris has given (CEO's RARELY if EVER, speculate about next year's earnings unless they're damned sure, or a crook), we're likely looking at 30M, and that's without any additional licensing deals or acquisitions. That's putting the company today at a value of 2.36x earnings. Merus, by comparison is running at a valuation of closer to 5x earnings and is not EBITA positive with a garbage outlook. To reach the 'lofty garbage' levels of Merus (a dog, by most people's standards), TRX would need to be trading around $1.40. This is without mentioning Uracyst or Bezalip or Bilastine. Buy as much as possible. The risk of an overweight position in this case is certainly justified.